This Fortune article discussed how BERG is reinventing drug R&D to change healthcare. For the full article, click here.

  STAT reporter, Casey Ross, leads a thought provoking conversation with key industry experts about how drug developers, doctors, and bioinformatics researchers are using artificial intelligence to revolutionize the search for breakthrough therapies. Hear from Niven R. Narain, PhD., BERG’s Co-Founder, President and CEO and other industry leaders. For the full panel session, click here.

STAT reporter, Casey Ross, leads a thought-provoking conversation with key industry experts about how drug developers, doctors, and bioinformatics researchers are using artificial intelligence to revolutionize the search for breakthrough therapies. Hear from Niven R. Narain, PhD., BERG’s Co-Founder, President and CEO and other industry leaders. For the full panel session, click here.

Harry Glorikian interviews Niven R. Narain, PhD., Co-Founder, President and CEO of BERG to discuss BERG’s philosophy: to combine a systems biology architecture with patients’ demographic data and clinical outcome data, and then apply Bayesian artificial intelligence algorithms to drive better understanding of diseases. For the full interview, click here.    

BERG was featured in MediaPlanet’s “Rare Disease Campaign” to raise awareness surrounding rare diseases and BERG’s commitment to the rare disease community. To hear from BERG’s CEO on the panel of experts discussing advancements in the research process, click here.

“We are turning the drug-discovery paradigm upside down by using patient-driven biology and data to derive more predictive hypotheses, rather than the traditional trial-and-error approach,” said Niven Narain, PhD., BERG’s Co-founder, President and CEO. To read the full article, click here.